Literature DB >> 1701445

Epitopes functional in neutralization of varicella-zoster virus.

B Forghani1, K W Dupuis, N J Schmidt.   

Abstract

By competition neutralization assay using monoclonal antibodies (MAbs) to varicella-zoster virus (VZV) glycoproteins (gps), we attempted to determine the topographical relationship of epitopes which are functional in VZV neutralization. MAbs against gpI interfered moderately to strongly with neutralization of MAbs against gpIII, and one antigenic domain with two distinct epitopes was identified on gpIII. Competition neutralization assays performed with MAbs to gpI revealed at least three distinct antigenic domains: the first contained two complement-dependent neutralizing epitopes; the second contained five complement-dependent neutralizing, overlapping epitopes and one nonneutralizing, nonoverlapping epitope; and the third contained one complement-enhanced neutralizing epitope. Competition neutralization assays performed with MAbs to gpIV showed one antigenic domain with two distinct epitopes which competed with nonneutralizing gpI MAbs. gpII did not interfere with neutralization of gpI, gpIII, or gpIV. Our data suggest that neutralizing and nonneutralizing MAbs can interfere with the action of viral neutralization either by inhibition or by enhancement. This report describes the epitope mapping of VZV gps by a functional biological assay.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1701445      PMCID: PMC268214          DOI: 10.1128/jcm.28.11.2500-2506.1990

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  33 in total

1.  Improved yields of cell-free varicella-zoster virus.

Authors:  N J Schmidt; E H Lennette
Journal:  Infect Immun       Date:  1976-09       Impact factor: 3.441

2.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

3.  Enhanced neutralization of La Crosse virus by the binding of specific pairs of monoclonal antibodies to the G1 glycoprotein.

Authors:  L Kingsford
Journal:  Virology       Date:  1984-07-30       Impact factor: 3.616

4.  Conformational changes at topologically distinct antigenic sites on the influenza A/PR/8/34 virus HA molecule are induced by the binding of monoclonal antibodies.

Authors:  M Lubeck; W Gerhard
Journal:  Virology       Date:  1982-04-15       Impact factor: 3.616

5.  Monoclonal antibodies to Sindbis virus glycoprotein E1 can neutralize, enhance infectivity, and independently inhibit haemagglutination or haemolysis.

Authors:  A C Chanas; E A Gould; J C Clegg; M G Varma
Journal:  J Gen Virol       Date:  1982-01       Impact factor: 3.891

6.  Neutralizing antibody responses to varicella-zoster virus.

Authors:  N J Schmidt; E H Lennette
Journal:  Infect Immun       Date:  1975-09       Impact factor: 3.441

7.  New common nomenclature for glycoprotein genes of varicella-zoster virus and their glycosylated products.

Authors:  A J Davison; C M Edson; R W Ellis; B Forghani; D Gilden; C Grose; P M Keller; A Vafai; Z Wroblewska; K Yamanishi
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

8.  Monoclonal antibodies against three major glycoproteins of varicella-zoster virus.

Authors:  C Grose; D P Edwards; W E Friedrichs; K A Weigle; W L McGuire
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

9.  Varicella-zoster virus envelope glycoproteins: biochemical characterization and identification in clinical material.

Authors:  C M Edson; B A Hosler; C A Poodry; R T Schooley; D J Waters; D A Thorley-Lawson
Journal:  Virology       Date:  1985-08       Impact factor: 3.616

10.  Viral epitopes and monoclonal antibodies: isolation of blocking antibodies that inhibit virus neutralization.

Authors:  R J Massey; G Schochetman
Journal:  Science       Date:  1981-07-24       Impact factor: 47.728

View more
  5 in total

1.  Mutational analysis of the role of glycoprotein I in varicella-zoster virus replication and its effects on glycoprotein E conformation and trafficking.

Authors:  S Mallory; M Sommer; A M Arvin
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Varicella-zoster virus glycoprotein I is essential for growth of virus in Vero cells.

Authors:  J I Cohen; H Nguyen
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

3.  Enhanced Potency and Persistence of Immunity to Varicella-Zoster Virus Glycoprotein E in Mice by Addition of a Novel BC02 Compound Adjuvant.

Authors:  Junli Li; Lili Fu; Yang Yang; Guozhi Wang; Aihua Zhao
Journal:  Vaccines (Basel)       Date:  2022-03-29

Review 4.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

5.  Varicella-zoster virus glycoprotein gpI/gpIV receptor: expression, complex formation, and antigenicity within the vaccinia virus-T7 RNA polymerase transfection system.

Authors:  Z Yao; W Jackson; B Forghani; C Grose
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.